Arrowhead Pharmaceuticals Presents Preclinical Data on Renal Cell Carcinoma Program at AACR 2016
April 18 2016 - 2:00PM
Business Wire
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented a
poster on ARC-HIF2, its preclinical development program targeting
HIF2-α for the treatment of renal cell carcinoma (RCC), at the
American Association for Cancer Research Annual Meeting 2016
(AACR16), in New Orleans. ARC-HIF2 is Arrowhead’s first RNAi
therapeutic program to target tissues outside the liver.
The poster titled, “Novel HIF-2α targeted RNAi therapeutic for
renal cell carcinoma” (abstract 2064), describes data from various
stages of development of ARC-HIF2, including RNAi trigger
selection, HIF2-α target validation, delivery and targeting ligand
validation, and multiple RCC tumor models. These data show that
important advancements are being made in this program and for
Arrowhead’s Dynamic PolyconjugateTM (DPCTM) delivery platform
generally, including the following key findings:
- Proof-of-concept ligand dependent,
functional delivery was demonstrated using the DPC targeted
delivery platform
- Silencing HIF2-α expression by RNA
interference resulted in reduction of HIF-2α regulated genes
- In two different RCC tumor bearing
mouse models, ARC-HIF2 inhibited tumor growth and promoted tumor
cell death and structural degeneration
A copy of the poster presentation is available on the Events and
Presentations page under the Investors section of the Arrowhead
website.
About Arrowhead PharmaceuticalsArrowhead Pharmaceuticals
develops medicines that treat intractable diseases by silencing the
genes that cause them. Using a broad portfolio of RNA chemistries
and efficient modes of delivery, Arrowhead therapies trigger the
RNA interference mechanism to induce rapid, deep, and durable
knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific
protein. Arrowhead’s RNAi-based therapeutics leverage this natural
pathway of gene silencing. The company’s pipeline includes ARC-520
and ARC-521 for chronic hepatitis B virus, ARC-AAT for liver
disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for
hereditary angioedema and thromboembolic disorders, ARC-LPA for
cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.
For more information please visit www.arrowheadpharma.com, or
follow us on Twitter @ArrowheadPharma. To be added to the Company's
email list and receive news directly, please visit
http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation
Reform Act:This news release contains forward-looking
statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995. These
statements are based upon our current expectations and speak only
as of the date hereof. Our actual results may differ materially and
adversely from those expressed in any forward-looking statements as
a result of various factors and uncertainties, including our
ability to finance our operations, the future success of our
scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of
our intellectual property rights. Our most recent Annual Report on
Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss
some of the important risk factors that may affect our business,
results of operations and financial condition. We assume no
obligation to update or revise forward-looking statements to
reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead
Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160418005487/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone,
CFA626-304-3400ir@arrowheadpharma.comorInvestor
Relations:The Trout GroupChad
Rubin646-378-2947ir@arrowheadpharma.comorMedia:Russo
PartnersMatt Middleman,
M.D.212-845-4272matt.middleman@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2023 to Apr 2024